内容紹介
Chemotherapy for GI and Pancreatic NETs
Summary
Neuroendocrine tumors(NETs)describe a heterogeneous group of tumors with a wide range of morphologic, functional, and behavioral characteristics. Pancreatic neuroendocrine tumors(pNET)are a subset of NETs which are increasing in incidence and prevalence. These tumors are generally slow growing and behave in an indolent fashion. However, when these tumors spread they can be life threatening and difficult to treat with current modalities. Recently, the basic treatment for pNET was changed with the approval of two targeted agents, sunitinib and everolimus. Clinical trials conducting various combinations of somatostatin analogues, mTOR inhibitors, tyrosine kinase inhibitors, and cytotoxic agents are ongoing under-evaluation, and a multitargeted approach to therapy will translate into improved patient outcomes.
要旨 神経内分泌腫瘍はまれな腫瘍であり,従来より治療開発の遅れによりほとんど有効な治療はなかった。低分化型のNECについては小細胞肺癌に準じての治療が選択され,高分化型のNET G1/G2に対しては第Ⅲ相臨床試験の結果から,エベロリムス,スニチニブの有効性が示され,分子生物学に基づく治療体系が急速に導入されつつある。
目次
Summary
Neuroendocrine tumors(NETs)describe a heterogeneous group of tumors with a wide range of morphologic, functional, and behavioral characteristics. Pancreatic neuroendocrine tumors(pNET)are a subset of NETs which are increasing in incidence and prevalence. These tumors are generally slow growing and behave in an indolent fashion. However, when these tumors spread they can be life threatening and difficult to treat with current modalities. Recently, the basic treatment for pNET was changed with the approval of two targeted agents, sunitinib and everolimus. Clinical trials conducting various combinations of somatostatin analogues, mTOR inhibitors, tyrosine kinase inhibitors, and cytotoxic agents are ongoing under-evaluation, and a multitargeted approach to therapy will translate into improved patient outcomes.
要旨 神経内分泌腫瘍はまれな腫瘍であり,従来より治療開発の遅れによりほとんど有効な治療はなかった。低分化型のNECについては小細胞肺癌に準じての治療が選択され,高分化型のNET G1/G2に対しては第Ⅲ相臨床試験の結果から,エベロリムス,スニチニブの有効性が示され,分子生物学に基づく治療体系が急速に導入されつつある。